Developer docs
API playgroundTry for free, no card

Search company profiles

Immune Insight

Full company profile

uuid002dkm8

Namestring
Immune Insight
Legal namestring
Immune Insight
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Immune Insight is a France-based Contract Research Organization founded in 2016 as a spin-off from academic research at the Institut Pasteur de Lille. It specializes in ex-vivo and in-vivo assessment of compounds on the immune system, with a particular focus on regulatory T cells (Tregs), serving pharmaceutical and biotechnology clients developing therapeutics in oncology, autoimmunity, and inflammatory diseases. The company's portfolio centers on three service pillars: a proprietary TregSign Kit based on an 80-gene molecular signature that delivers single-assay transcriptomic profiling across eight Treg functional clusters; a cellular insight suite covering PBMC/Treg suppression assays, immunomonitoring, immunophenotyping, and secretion, viability, and tumor infiltration analyses; and animal insight services using syngeneic and PDX-Like humanized cancer models in SCID mice for preclinical efficacy and toxicity studies.

The business operates on a professional-services CRO model with quote-based, project-specific pricing and a direct B2B sales motion that begins with needs discovery, proceeds through custom experimental design, and ends with comprehensive technical reporting and data review sessions. Immune Insight monetizes its privileged access to the Pasteur and CNRS technological ecosystem (animal housing, imaging platforms, shared facilities) and the deep domain expertise of its scientific founders, who hold more than 20 years of onco-immunology and Treg biology experience. The company is privately held, headquartered at the Institut de Biologie de Lille on the Institut Pasteur de Lille campus, and reports a headcount of 1-10 employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLille, France
HQ citystring
Lille
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research organization, regulatory T cells, preclinical immunology services, immuno-oncology research, humanized cancer models
Industry3 codes
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Contract Research Organization / Preclinical Immunology Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

CRO providing specialized research services to pharmaceutical and biotech companies for drug discovery and development. Services include ex-vivo and in-vivo assessment of compounds on the immune system and regulatory T cells. Revenue generated through custom-designed experimental protocols and comprehensive technical/scientific reports delivered to clients.

immune-insight.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Immune Insight is a contract research organization (CRO) that delivers ex-vivo and in-vivo preclinical assessment of compounds on the immune system, with a specialist focus on regulatory T cells (Tregs). Service offerings include molecular transcriptomic profiling via the proprietary TregSign Kit, cellular immunomonitoring/immunophenotyping assays, and custom humanized in vivo cancer models for efficacy and safety studies, supplied to pharmaceutical and biotech drug discovery programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Complete transcriptomic study of Tregs and their microenvironment in a single assay
+1 more record
Product overview1 text field

Immune Insight is a Contract Research Organization (CRO) specializing in ex-vivo and in-vivo assessment of compounds on the immune system, specifically regulatory T cells (Tregs). The company's portfolio includes the TregSign Kit for molecular transcriptomic analysis, immunomonitoring services (PBMC/Treg Suppression Assay, immunophenotyping), and pre-clinical in vivo cancer models (PDX-Like models). These offerings support drug discovery and development through lead identification, safety assessment, immunotoxicity evaluation, and patient stratification in the fields of cancer, autoimmunity, and inflammatory diseases.

Product and service4 records
1TregSign Kit
CategoryPreclinical immunology / molecular signature assay
Description

A molecular signature tool based on expression of 80 genes related to natural Tregs, induced Tregs, and their microenvironment, enabling complete transcriptomic study of regulatory T cells in a single assay. It establishes 8 gene clusters — Phenotype, Suppressive function, Expansion, Induction, Adhesion, Activation state, Migration, Infiltration, and Plasticity — and determines the impact of a candidate molecule on Tregs and their microenvironment. Targeted at pharmaceutical and biotech drug discovery programs in oncology, autoimmunity, and inflammatory diseases.

2PBMC/Treg Suppression Assay
CategoryPreclinical immunology / cellular assay service
Description

An immunomonitoring and characterization method that assesses the suppressive function of regulatory T cells through standardized suppression assays on PBMCs and Tregs. Designed for pharmaceutical and biotech researchers evaluating compound efficacy and safety on Treg biology during preclinical development.

3Immunomonitoring and Immunophenotyping Services
CategoryPreclinical immunology / immunophenotyping service
Description

A comprehensive suite of cellular assays assessing compound efficacy and safety on Treg Biology, including Suppressive Function Assays, Recruitment Analysis, Secretion Profile, Cell Death & Viability Assay, and Tumour Infiltration Analysis. Targeted at pharma and biotech developers needing deep immunophenotyping readouts for lead characterization and safety profiling.

4PDX-Like In Vivo Cancer Models
CategoryPreclinical in vivo oncology models service
Description

Custom-made preclinical in vivo cancer models using humanized SCID mice (PDX-Like) and syngeneic models, enabling complete monitoring of disease advancement, organ infiltration, and toxicity for compound efficacy and safety assessment. Provided to pharmaceutical and biotechnology clients for oncology drug development programs.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Caprion Biosciences
TypeDirect peer
Description

Specialized immunology and proteomics CRO providing biomarker and immune monitoring services to biopharma. Direct comparability through shared focus on immunology-based custom assays for drug discovery and development.

TypeEmerging player
Description

Preclinical research services provider with in vivo oncology and toxicology capabilities. Comparable as a smaller specialist CRO offering preclinical in vivo work overlapping with Immune Insight's PDX-like cancer model offerings.

TypeBroad incumbent
Description

World's largest clinical CRO with growing specialty/immuno-oncology lab services including biomarker strategy and translational work. Incumbent peer serving similar pharma/biotech customers at much larger scale.

TypeBroad incumbent
Description

Major clinical and preclinical CRO with strong central lab, biomarker, and immunoassay capabilities. Comparable as a broad-scope incumbent offering overlapping immunology and biomarker services to pharma/biotech.

TypeDirect peer
Description

Specialty CRO offering immune monitoring, flow cytometry, and biomarker assay services to pharma and biotech. Highly comparable to Immune Insight in serving immuno-oncology and inflammation drug developers with custom assay development and sample analysis.

TypeEmerging player
Description

Specialty bioanalytical and biomarker CRO with deep immunology expertise in immunogenicity, cell-based assays, and flow cytometry. Comparable as an immunology-focused specialty services peer serving therapeutic developers.

TypeDirect peer
Description

French preclinical CRO with strong oncology and pharmacology capabilities, including in vivo pharmacology and translational services. Comparable as a similarly sized France-headquartered specialty CRO serving biopharma R&D.

TypeBroad incumbent
Description

Large global CRO with extensive preclinical, discovery, and safety assessment services including immunology and oncology models. Relevant incumbent that can absorb immune-assessment work as part of broader CRO contracts.

TypeDirect peer
Description

French immuno-oncology contract research organization specializing in preclinical and translational immune monitoring services for cancer therapeutics. Closely comparable as a small, French specialty CRO focused on immunology biomarker and immune-monitoring work for pharma/biotech.

TypeBroad incumbent
Description

Global bioanalytical and clinical testing services platform with significant immunology, biomarker, and cell-based assay capabilities. Comparable as a large incumbent offering overlapping immunomonitoring and bioanalytical services at much greater scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Immune Insight

Contract Research Organization / Preclinical Immunology Servicesimmune-insight.com

What Immune Insight does

Immune Insight is a France-based Contract Research Organization founded in 2016 as a spin-off from academic research at the Institut Pasteur de Lille. It specializes in ex-vivo and in-vivo assessment of compounds on the immune system, with a particular focus on regulatory T cells (Tregs), serving pharmaceutical and biotechnology clients developing therapeutics in oncology, autoimmunity, and inflammatory diseases. The company's portfolio centers on three service pillars: a proprietary TregSign Kit based on an 80-gene molecular signature that delivers single-assay transcriptomic profiling across eight Treg functional clusters; a cellular insight suite covering PBMC/Treg suppression assays, immunomonitoring, immunophenotyping, and secretion, viability, and tumor infiltration analyses; and animal insight services using syngeneic and PDX-Like humanized cancer models in SCID mice for preclinical efficacy and toxicity studies.

The business operates on a professional-services CRO model with quote-based, project-specific pricing and a direct B2B sales motion that begins with needs discovery, proceeds through custom experimental design, and ends with comprehensive technical reporting and data review sessions. Immune Insight monetizes its privileged access to the Pasteur and CNRS technological ecosystem (animal housing, imaging platforms, shared facilities) and the deep domain expertise of its scientific founders, who hold more than 20 years of onco-immunology and Treg biology experience. The company is privately held, headquartered at the Institut de Biologie de Lille on the Institut Pasteur de Lille campus, and reports a headcount of 1-10 employees.

Immune Insight firmographics

Firmographics
Name
Immune Insight
Legal name
Immune Insight
Website
https://immune-insight.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Immune Insight industry classification

Industry
Product category
Contract Research Organization / Preclinical Immunology Services
NAICS
Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs

Keywords

  • Contract research organization
  • Regulatory T cells
  • Preclinical immunology services
  • Immuno-oncology research
  • Humanized cancer models

Where Immune Insight is headquartered

Location

Headquarters

HQ city
Lille
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Immune Insight business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Contract Research Services: CRO providing specialized research services to pharmaceutical and biotech companies for drug discovery and development. Services include ex-vivo and in-vivo assessment of compounds on the immune system and regulatory T cells. Revenue generated through custom-designed experimental protocols and comprehensive technical/scientific reports delivered to clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Immune Insight product offering

Product offering

Core offering

Immune Insight is a contract research organization (CRO) that delivers ex-vivo and in-vivo preclinical assessment of compounds on the immune system, with a specialist focus on regulatory T cells (Tregs). Service offerings include molecular transcriptomic profiling via the proprietary TregSign Kit, cellular immunomonitoring/immunophenotyping assays, and custom humanized in vivo cancer models for efficacy and safety studies, supplied to pharmaceutical and biotech drug discovery programs.

Product overview

Immune Insight is a Contract Research Organization (CRO) specializing in ex-vivo and in-vivo assessment of compounds on the immune system, specifically regulatory T cells (Tregs). The company's portfolio includes the TregSign Kit for molecular transcriptomic analysis, immunomonitoring services (PBMC/Treg Suppression Assay, immunophenotyping), and pre-clinical in vivo cancer models (PDX-Like models). These offerings support drug discovery and development through lead identification, safety assessment, immunotoxicity evaluation, and patient stratification in the fields of cancer, autoimmunity, and inflammatory diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • TregSign Kit A molecular signature tool based on expression of 80 genes related to natural Tregs, induced Tregs, and their microenvironment, enabling complete transcriptomic study of regulatory T cells in a single assay. It establishes 8 gene clusters — Phenotype, Suppressive function, Expansion, Induction, Adhesion, Activation state, Migration, Infiltration, and Plasticity — and determines the impact of a candidate molecule on Tregs and their microenvironment. Targeted at pharmaceutical and biotech drug discovery programs in oncology, autoimmunity, and inflammatory diseases.
  • PBMC/Treg Suppression Assay An immunomonitoring and characterization method that assesses the suppressive function of regulatory T cells through standardized suppression assays on PBMCs and Tregs. Designed for pharmaceutical and biotech researchers evaluating compound efficacy and safety on Treg biology during preclinical development.
  • Immunomonitoring and Immunophenotyping Services A comprehensive suite of cellular assays assessing compound efficacy and safety on Treg Biology, including Suppressive Function Assays, Recruitment Analysis, Secretion Profile, Cell Death & Viability Assay, and Tumour Infiltration Analysis. Targeted at pharma and biotech developers needing deep immunophenotyping readouts for lead characterization and safety profiling.
  • PDX-Like In Vivo Cancer Models Custom-made preclinical in vivo cancer models using humanized SCID mice (PDX-Like) and syngeneic models, enabling complete monitoring of disease advancement, organ infiltration, and toxicity for compound efficacy and safety assessment. Provided to pharmaceutical and biotechnology clients for oncology drug development programs.

Quantifiable outcome

  • Complete transcriptomic study of Tregs and their microenvironment in a single assay
  • +1 more outcomes

Companies that use Immune Insight

Customer profile

Segments2 records

Ideal customer profiles2 records

Immune Insight technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Immune Insight partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves7 records

Expansion highlights4 records

Immune Insight competitors and assessment

Company assessment

Direct peers

  • Caprion Biosciences: Specialized immunology and proteomics CRO providing biomarker and immune monitoring services to biopharma. Direct comparability through shared focus on immunology-based custom assays for drug discovery and development.
  • CellCarta (formerly Caprion Biosciences): Specialty CRO offering immune monitoring, flow cytometry, and biomarker assay services to pharma and biotech. Highly comparable to Immune Insight in serving immuno-oncology and inflammation drug developers with custom assay development and sample analysis.
  • Oncodesign: French preclinical CRO with strong oncology and pharmacology capabilities, including in vivo pharmacology and translational services. Comparable as a similarly sized France-headquartered specialty CRO serving biopharma R&D.
  • Explicyte: French immuno-oncology contract research organization specializing in preclinical and translational immune monitoring services for cancer therapeutics. Closely comparable as a small, French specialty CRO focused on immunology biomarker and immune-monitoring work for pharma/biotech.

Emerging players

  • Inotiv: Preclinical research services provider with in vivo oncology and toxicology capabilities. Comparable as a smaller specialist CRO offering preclinical in vivo work overlapping with Immune Insight's PDX-like cancer model offerings.
  • BioAgilytix: Specialty bioanalytical and biomarker CRO with deep immunology expertise in immunogenicity, cell-based assays, and flow cytometry. Comparable as an immunology-focused specialty services peer serving therapeutic developers.

Broad incumbents

  • IQVIA: World's largest clinical CRO with growing specialty/immuno-oncology lab services including biomarker strategy and translational work. Incumbent peer serving similar pharma/biotech customers at much larger scale.
  • Labcorp Drug Development: Major clinical and preclinical CRO with strong central lab, biomarker, and immunoassay capabilities. Comparable as a broad-scope incumbent offering overlapping immunology and biomarker services to pharma/biotech.
  • Charles River Laboratories: Large global CRO with extensive preclinical, discovery, and safety assessment services including immunology and oncology models. Relevant incumbent that can absorb immune-assessment work as part of broader CRO contracts.
  • Eurofins Scientific: Global bioanalytical and clinical testing services platform with significant immunology, biomarker, and cell-based assay capabilities. Comparable as a large incumbent offering overlapping immunomonitoring and bioanalytical services at much greater scale.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Immune Insight financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Immune Insight leadership team

Management profile

Number of profiles

Profiles4 records

Immune Insight funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Immune Insight M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immune Insight

What does Immune Insight do?

Immune Insight is a contract research organization (CRO) that delivers ex-vivo and in-vivo preclinical assessment of compounds on the immune system, with a specialist focus on regulatory T cells (Tregs). Service offerings include molecular transcriptomic profiling via the proprietary TregSign Kit, cellular immunomonitoring/immunophenotyping assays, and custom humanized in vivo cancer models for efficacy and safety studies, supplied to pharmaceutical and biotech drug discovery programs.

Is Immune Insight a public or private company?

Immune Insight is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Immune Insight founded?

Immune Insight was founded in 2016. It employs 1 to 10 people.

Where is Immune Insight based?

Immune Insight is headquartered in Lille, France, in the Europe region.

How does Immune Insight make money?

One revenue line is on record: contract Research Services.

Who are Immune Insight's main competitors?

Direct peers on record are Caprion Biosciences, CellCarta (formerly Caprion Biosciences), Oncodesign and Explicyte. Emerging players are Inotiv and BioAgilytix. Broad incumbents are IQVIA, Labcorp Drug Development, Charles River Laboratories and Eurofins Scientific.

Does Immune Insight have an API?

No public API is recorded for Immune Insight.

What industry is Immune Insight in?

Immune Insight's product category is Contract Research Organization / Preclinical Immunology Services. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 5417 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales